BACK (IMAC Holdings) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2025)


What is IMAC Holdings ROE % Adjusted to Book Value?

IMAC Holdings BACK ROE % Adjusted to Book Value is 0.00% as of Sep. 2025. The stock has 7 warning signs investors should review.

IMAC Holdings's ROE % for the quarter that ended in Sep. 2025 was 0.00%. IMAC Holdings's PB Ratio for the quarter that ended in Sep. 2025 was N/A. IMAC Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was N/A.

IMAC Holdings ROE % Adjusted to Book Value Related Terms

IMAC Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for IMAC Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMAC Holdings ROE % Adjusted to Book Value Chart

IMAC Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -24.86 -49.30 -114.91 0.00 0.00

IMAC Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BACK vs FCHS, NHLG, NIVF: ROE % Adjusted to Book Value Comparison

For the Medical Care Facilities subindustry, IMAC Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IMAC Holdings ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, IMAC Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where IMAC Holdings's ROE % Adjusted to Book Value falls into.


IMAC Holdings ROE % Adjusted to Book Value Calculation

IMAC Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

IMAC Holdings's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
IMAC Holdings (BACK) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IMAC Holdings and its competitors.
Is IMAC Holdings' ROE % Adjusted to Book Value too high?
IMAC Holdings' current ROE % Adjusted to Book Value is 0.00%.
How does IMAC Holdings' ROE % Adjusted to Book Value compare to FCHS and NHLG?
IMAC Holdings' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on IMAC Holdings and its competitors. IMAC Holdings's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For IMAC Holdings (BACK), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.